Estimating the response and economic burden of rheumatoid arthritis patients treated with biologic disease-modifying antirheumatic drugs in Taiwan using the National Health Insurance Research Database (NHIRD)
Journal
PloS one
Journal Volume
13
Journal Issue
4
Pages
e0193489
Date Issued
2018-04-06
Author(s)
Shi, Qiang
Treuer, Tamas
Wang, Bruce C M
Gaich, Carol L
Lee, Chien-Hsun
Wu, Wen-Shuo
Furnback, Wesley
Tang, Chao-Hsiun
Abstract
Previous studies in Taiwan utilizing the Taiwan's National Health Insurance Database (NHIRD) have estimated the direct healthcare costs of RA patients, but they have not focused on patients on bDMARDs, or considered patients' response to therapy.
Subjects
RISK; PREVALENCE; COMORBIDITY; MANIFESTATIONS; OSTEOPOROSIS; CONSORTIUM; MORTALITY; FREQUENCY; FRACTURE; PEOPLE
SDGs
Other Subjects
disease modifying antirheumatic drug; glucocorticoid; adalimumab; antirheumatic agent; biological product; etanercept; adult; algorithm; Article; data base; disease burden; female; follow up; health care cost; health care utilization; health economics; human; longitudinal study; major clinical study; male; medication compliance; national health insurance; retrospective study; rheumatoid arthritis; Taiwan; treatment response; cost of illness; economics; factual database; health care cost; insurance; middle aged; public health; rheumatoid arthritis; treatment outcome; very elderly; Adalimumab; Aged, 80 and over; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Cost of Illness; Databases, Factual; Etanercept; Female; Health Care Costs; Humans; Insurance Claim Review; Male; Middle Aged; National Health Programs; Retrospective Studies; Taiwan; Treatment Outcome
Publisher
PUBLIC LIBRARY SCIENCE
Type
journal article